Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase, and has been shown to delay disease in a mouse model of neuropsychiatric disorders. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline (150 mg/d) for 4 weeks as an open-label adjunct to antipsychotic medication to 22 patients with schizophrenia. The Positive and Negative Syndrome Scale for schizophrenia showed statistically significant and robust clinical improvements with minocycline treatment, which were maintained at follow-up evaluation 4 weeks after the end of minocycline treatment. There were no adverse events. These results suggest that minocycline may be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for "boosting" antipsychotic efficacy and for treating schizophrenia.

No abstract

No abstract

We investigate a novel class of neural stochastic resonance (SR) exhibiting error-free information transfer. Unlike conventional neural SR, where the decrease of a system's response with too much noise is associated with an increase in the baseline firing rate, here the bell-shaped SR behavior of the input-output cross correlation emerges versus increasing input noise in spite of no significant increase of the baseline firing rate. The neuron thus acts as an error-free detector for weak signals. An integrate-and-fire model with short-term synaptic depression convincingly validates our experimental findings for SR in the human tactile blink reflex.

In this open-label pilot study, patients treated with YGS showed a statistically significant reduction on clinician-rated scales. The present findings suggest that an adjunction of YGS might be effective for treatment-resistant schizophrenia.